Targeting immune effector molecules to human tumor cells through genetic delivery of 5T4-specific scFv fusion proteins

Cancer Gene Therapy

Volumn 9, Issue 11, 2002, Pages 884-896

  Myers, Kevin A ^a   Ryan, Matthew G ^a   Stern, Peter L ^b   Shaw, David M ^b   Embleton, M Jim ^b   Kingsman, Susan M ^a   Carroll, Miles W ^a  

^a OXFORD BIOMEDICA UK LTD   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

5T4 oncofetal antigen; Genetic delivery; Immunotherapy; Murine Leukemia Virus; ScFv fusion proteins; Tumor associated antgens

Indexed keywords

B7 ANTIGEN; CHIMERIC PROTEIN; GLYCOPROTEIN; HYBRID PROTEIN; IMMUNOGLOBULIN G1; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR ANTIGEN; VIRUS VECTOR;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; CANCER; CANCER IMMUNOTHERAPY; CELL SURFACE; CELLULAR IMMUNITY; CHIMERA; CYTOLYSIS; DRUG EFFECT; DRUG EFFICACY; GENE THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; METASTASIS; MURINE LEUKEMIA VIRUS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SECRETION; TUMOR CELL LINE; VIRAL GENE DELIVERY SYSTEM;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; BASE SEQUENCE; CELL LINE; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOTHERAPY; KIDNEY; MOLECULAR SEQUENCE DATA; RECOMBINANT FUSION PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED;

MURINAE; MURINE LEUKEMIA VIRUS;

EID: 0036841131     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700513     Document Type: Article

References (52)

1. Durrant LG, Maxwell-Armstrong C, Buckley D, et al. A neoadjuvant clinical trial in colorectal cancer patients of the human anti-idiotypic antibody 105AD7, which mimics CD55. Clin Cancer Res. 2000;6:422-430.
2. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000;18:317-324.
3. Riethmuller G, Holz E, Schlimok G, et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: Seven-year outcome of a multicenter randomized trial. J Clin Oncol. 1998;16:1788-1794.
4. Divgi CR, Scott AM, Dantis L, et al. Phase I radioimmunotherapy trial with iodine-131-CC49 in metastatic colon carcinoma. J Nucl Med. 1995;36:586-592.
5. 131I-anti-HCC mAb. Phase I/II clinical trials. J Cancer Res Clin Oncol. 1998;124:275-280.
6. Appelbaum FR. Antibody-targeted therapy for myeloid leukemia. Semin Hematol. 1999;36:2-8.
7. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol. 1999;26:60-70.
8. Tse E, Rabbitts TH. Intracellular antibody-caspase-mediated cell killing: An approach for application in cancer therapy. Proc Natl Acad Sci USA. 2000;97:12266-12271.
9. Gutheil JC, Campbell TN, Pierce PR, et al. Targeted antiangiogenic therapy for cancer using Vitaxin: A humanized monoclonal antibody to the integrin alphavbeta3. Clin Cancer Res. 2000;6:3056-3061.
10. Vollmers HP, Zimmermann U, Krenn V, et al. Adjuvant therapy for gastric adenocarcinoma with the apoptosis-inducing human monoclonal antibody SC-1: First clinical and histopathological results. Oncol Rep. 1998;5:549-552.
11. Cooley S, Burns LJ, Repka T, Miller JS. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol. 1999;27:1533-1541.
12. Grillo-Lopez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: First monoclonal antibody approved for the treatment of lymphoma. Semin Oncol. 1999;26:66-73.
13. Sharkey RM, Gold DV, Aninipot R, et al. Comparison of tumor targeting in nude mice by murine monoclonal antibodies directed against different human colorectal cancer antigens. Cancer Res. 1990;50:828s-834s.
14. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res. 1992;52:3402-3408.
15. Khazaeli MB, Conry RM, LoBuglio AF. Human immune response to monoclonal antibodies. J Immunother. 1994;15:42-52.
16. Adams GP, McCartney JE, Tai MS, et al. Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res. 1993;53:4026-4034.
17. Milenic DE, Yokota T, Filpula DR, et al. Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res. 1991;51:6363-6371.
18. Clark MR. IgG effector mechanisms. Chem Immunol. 1997;65:88-110.
19. Boussiotis VA, Freeman GJ, Gribben JG, Nadler LM. The role of B7-1/B7-2:CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response. Immunol Rev. 1996;153:5-26.
20. Griffiths L, Binley K, Iqball S, et al. The macrophage - A novel system to deliver gene therapy to pathological hypoxia. Gene Ther. 2000;7:255-262.
21. Whittington HA, Ashworth LJ, Hawkins RE. Recombinant adenoviral delivery for in vivo expression of scFv antibody fusion proteins. Gene Ther. 1998;5:770-777.
22. Hu Z, Garen A. Intratumoral injection of adenoviral vectors encoding tumor-targeted immunoconjugates for cancer immunotherapy. Proc Natl Acad Sci USA. 2000;97:9221-9225.
23. Cochet O, Kenigsberg M, Delumeau I, et al. Intracellular expression of an antibody fragment-neutralizing p21 ras promotes tumor regression. Cancer Res. 1998;58:1170-1176.
24. Myers KA, Rahi-Saund V, Davison MD, Young JA, Cheater AJ, Stern PL. Isolation of a cDNA encoding 5T4 oncofetal trophoblast glycoprotein. An antigen associated with metastasis contains leucine-rich repeats. J Biol Chem. 1994;269:9319-9324.
25. Hole N, Stern PL. A 72 kD trophoblast glycoprotein defined by a monoclonal antibody. Br J Cancer. 1988;57:239-246.
26. Hole N, Stern PL. Isolation and characterization of 5T4, a tumour-associated antigen. Int J Cancer. 1990;45:179-184.
27. Southall PJ, Boxer GM, Bagshawe KD, Hole N, Bromley M, Stern PL. Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br J Cancer. 1990;61:89-95.
28. Jones H, Roberts G, Hole N, McDicken IW, Stern P. Investigation of expression of 5T4 antigen in cervical cancer. Br J Cancer. 1990;61:96-100.
29. Wrigley E, McGown A, Rennison J, et al. 5T4 oncofetal antigen expression in ovarian carcinoma. Int J Gynecol Cancer. 1995;5:269-274.
30. Starzynska T, Rahi V, Stern PL. The expression of 5T4 antigen in colorectal and gastric carcinoma. Br J Cancer. 1992;66:867-869.
31. Starzynska T, Marsh PJ, Schofield PF, Roberts SA, Myers KA, Stern PL. Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br J Cancer. 1994;69:899-902.
32. Forsberg G, Ohlsson L, Brodin T, et al. Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen. Br J Cancer. 2001;85:129-136.
33. Shaw DM, Embleton MJ, Westwater C, et al. Isolation of a high affinity scFv from a monoclonal antibody recognising the oncofoetal antigen 5T4. Biochim Biophys Acta. 2000;1524:238-246.
34. Landau NR, Littman DR. Packaging system for rapid production of murine leukemia virus vectors with variable tropism. J Virol. 1992;66:5110-5113.
35. Soneoka Y, Cannon PM, Ramsdale EE, et al. A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res. 1995;23:628-633.
36. Nambu M, Morita M, Watanabe H, et al. Regulation of Fc gamma receptor expression and phagocytosis of a human monoblast cell line U937. Participation of cAMP and protein kinase C in the effects of IFN-gamma and phorbol ester. J Immunol. 1989;143:4158-4165.
37. Primus FJ, Finch MD, Masci AM, Schlom J, Kashmiri SV. Self-reactive antibody expression by human carcinoma cells engineered with monoclonal antibody genes. Cancer Res. 1993;53:3355-3361.
38. Roovers RC, Henderikx P, Helfrich W, et al. High-affinity recombinant phage antibodies to the pan-carcinoma marker epithelial glycoprotein-2 for tumour targeting. Br J Cancer. 1998;78:1407-1416.
39. Velders MP, van Rhijn CM, Oskam E, Fleuren GJ, Warnaar SO, Litvinov SV. The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: Relevance for immunotherapy of carcinomas. Br J Cancer. 1998;78:478-483.
40. + T cells by B7-transfected melanoma cells. Science. 1993;259:368-370.
41. Baskar S, Ostrand-Rosenberg S, Nabavi N, Nadler LM, Freeman GJ, Glimcher LH. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc Natl Acad Sci USA. 1993;90:5687-5690.
42. Chen L, McGowan P, Ashe S, et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med. 1994;179:523-532.
43. Carroll MW, Overwijk WW, Surman DR, Tsung K, Moss B, Restifo NP. Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen. J Natl Cancer Inst. 1998;90:1881-1887.
44. Gilligan MG, Knox P, Weedon S, et al. Adenoviral delivery of B7-1 (CD80) increases the immunogenicity of human ovarian and cervical carcinoma cells. Gene Ther. 1998;5:965-974.
45. Holliger P, Manzke O, Span M, et al. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3xanti-CEA bispecific diabodies and B7xanti-CEA bispecific fusion proteins. Cancer Res. 1999;59:2909-2916.
46. Ragnhammar P, Frodin J-E, Hjelm A-L, et al. Different dose regimens of the mouse monoclonal antibody 17-1A for therapy of patients with metastatic colorectal carcinoma. Int J Oncol. 1995;7:1049-1056.
47. Juweid ME, Hajjar G, Swayne LC, et al. Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma. Cancer. 1999;85:1828-1842.
48. LoBuglio AF, Wheeler RH, Trang J, et al. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA. 1989;86:4220-4224.
49. Gruber R, van Haarlem LJ, Warnaar SO, Holz E, Riethmuller G. The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A. Cancer Res. 2000;60:1921-1926.
50. Clark JI, Alpaugh RK, von Mehren M, et al. Induction of multiple anti-c-erbB-2 specificities accompanies a classical idiotypic cascade following 2B1 bispecific monoclonal antibody treatment. Cancer Immunol Immunother. 1997;44:265-272.
51. Sacchi S, Federico M, Dastoli G, et al. Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab. Crit Rev Oncol Hematol. 2001;37:13-25.
52. Huls GA, Heijnen IA, Cuomo ME, et al. A recombinant, fully human monoclonal antibody with antitumor activity constructed from phage-displayed antibody fragments. Nat Biotechnol. 1999;17:276-281.